好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Outcomes in Transferred Stroke Patients with Large Vessel Occlusion (LVO) after IV rt-PA
Cerebrovascular Disease and Interventional Neurology
P2 - Poster Session 2 (5:30 PM-6:30 PM)
3-015
To study the relationship between rt-PA treatment and outcome in transferred LVO patients.
Limited data exists on outcomes post remote rt-PA treatment, in LVO patients.

A retrospective study was performed. Primary outcome measures were neurologic outcome, mortality, and TICI scores. Safety measure was symptomatic hemorrhage rate (SICH; NIHSS > 1 at ≤ 36hr).

 

From 1/2014-2/2018, 61 of 233 transferred rt-PA patients received MT. For the 233 patients group, median age was 73, median NIHSS 6, SICH rate 4% and discharge mRS≤2 rate 43%. Mean admission NIHSS was 13 and discharge 9. Mortality was 11%; 40% went home.

 

For the 61 rt-PA + MT patients, SICH rate was 2% and mortality 12%. Greater than 90% had AF.

 

Independently, 45 of the 233 patients had a pre rt-PA CTA with LVO. In these patients, median time to initial CTA was 77 min, and to repeat CTA 144 min. Of the LVOs, 80% were anterior circulation. Clot migration was seen in 5%. rt-PA recanalization rate was 11%. MT after rt-PA was performed in 65% (TICI ≥ 2b 89%). All patients with symptom onset to initial CTA ≤2 hours achieved TICI 2b or higher, and average time to recanalization was shorter (289 min  vs. 494 min >2h). Average NIHSS declined from 12 to 5 post MT.

 

Remote LVO IV rt-PA followed by MT is safe and effective. A significant minority of rt-PA LVO patients experienced recanalization suggesting repeat imaging for transferred patients is appropriate before MT. AF is common and may predict need for MT. Improved TICI score trended with shorter recanalization time and shorter symptom onset to initial CTA time. These data support the use of stroke systems of care for rapid triage and treatment of LVO patients.

 

Authors/Disclosures
Nikil Swamy, MD (CPMC)
PRESENTER
No disclosure on file
nobl barazangi, MD, PhD Dr. Barazangi has nothing to disclose.
No disclosure on file
Charlene Chen, MD (Denali Therapeutics) No disclosure on file
No disclosure on file
Christine S. Wong, MD No disclosure on file
Billy Gao, MD (Current Neurology Solutions) No disclosure on file
Jessica Choe, MD No disclosure on file
Ilana Spokoyny, MD (Sutter West Bay Medical Group) Dr. Spokoyny has nothing to disclose.
No disclosure on file
Joey English, MD, PhD No disclosure on file
Alan H. Yee, DO (University of California Davis, Dept of Neurology) Dr. Yee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janux Therapeutics. The institution of Dr. Yee has received research support from American Osteopathic Association .
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
David C. Tong, MD, FAHA No disclosure on file